Research on the mechanisms of taraxerol for the treatment of gastric cancer effect based on network pharmacology
Open Access
- 5 January 2022
- journal article
- research article
- Published by SAGE Publications in International Journal of Immunopathology and Pharmacology
Abstract
Background: Modern pharmacological studies have shown that traditional Chinese medicine (TCM) Taraxacum mongolicum possesses anti-cancer activity. Taraxerol (TRX) is a pentacyclic triterpene isolated from T. mongolicum, which is widely used in clinical treatment, and its anti-cancer effects have been extensively studied. However, the effects and molecular mechanism of TRX in gastric cancer (GC) have not been fully explicated. Methods: We used public databases to derive information on potential targets of TRX and proteins related to GC. Also, STRING and R3.6.2 software were used to analyze the protein–protein interaction (PPI). The Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were done to explain the potential mechanism underlying the regulatory role of TRX in GC. The role of TRX in GC was verified by 3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide (MTT) assay, apoptosis analysis, Transwell assay, and wound healing assay, and the key signaling pathways were verified. Results: We identified 135 potential targets for the treatment of GC via network pharmacological analysis. GO and KEGG enrichment analysis showed that steroid hormone receptor activity and the PI3K/AKT signaling pathway were the biological processes and pathways with the highest degree of enrichment. Additionally, cellular experiments revealed that TRX inhibited the proliferation, migration, and invasion of GC cells as well as induced G1 phase arrest and apoptosis in GC cells. Conclusion: Here, we used multi-target and multi-pathway network pharmacological analysis to verify the anti-cancer activity of TRX in GC. Also, in vitro experimental data were used to derive the potential molecular mechanism.Keywords
Funding Information
- Scientific Research Program of Hebei Provincial Administration of Traditional Chinese Medicine (2016053)
- National Natural Science Foundation of China (81202679)
This publication has 44 references indexed in Scilit:
- Effects of taraxerol and taraxeryl acetate on cell cycle and apoptosis of human gastric epithelial cell line AGSJournal of Chinese Integrative Medicine, 2011
- Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate DataJournal of Clinical Oncology, 2006
- Epidermal growth factor receptor (EGFR) signaling in cancerGene, 2006
- Exploiting the PI3K/AKT Pathway for Cancer Drug DiscoveryNature Reviews Drug Discovery, 2005
- Promoting apoptosis as a strategy for cancer drug discoveryNature Reviews Cancer, 2005
- Expression of survivin, cyclinD1, p21WAF1, caspase-3 in cervical cancer and its relation with prognosisJournal of Huazhong University of Science and Technology [Medical Sciences], 2005
- Expression Patterns of Cyclins D1, E and Cyclin-Dependent Kinase Inhibitors p21(Waf1/Cip1) and p27(Kip1) in Urothelial Carcinoma: Correlation with Other Cell-Cycle-Related Proteins (Rb, p53, Ki-67 and PCNA) and Clinicopathological FeaturesUrologia Internationalis, 2004
- GRB2: A pivotal protein in signal transductionSeminars in Oncology, 2001
- Cell Cycle Control and CancerScience, 1994
- The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinasesCell, 1993